DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2017/0165230 A1 RUDD Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2017/0165230 A1 RUDD Et Al US 201701 65230A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0165230 A1 RUDD et al. (43) Pub. Date: Jun. 15, 2017 (54) USE OF GSK-3 INHIBITORS OR A63L/433 (2006.01) ACTIVATORS WHICH MODULATE PD-1 OR A6IR 9/00 (2006.01) T-BET EXPRESSION TO MODULATE T (52) U.S. Cl. CELL IMMUNITY CPC .......... A61K 31/404 (2013.01); A61K 31/433 (2013.01); A61K 9/0053 (2013.01); A61 K (71) Applicant: Christopher RUDD, Montreal (CA) 38/10 (2013.01); A61K 31/426 (2013.01); A6 IK3I/506 (2013.01) (72) Inventors: Christopher RUDD, Montreal (CA): Dae Choon LEE, Springfield, MO (57) ABSTRACT (US); David Mark ROTHSTEIN, Pittsburgh, PA (US); Young Mee LEE, The present application generally relates to the discovery Springfield, MO (US) that glycogen synthase kinase 3 (GSK-3) is an upstream signalling molecule that controls PD-1 transcription and (21) Appl. No.: 15/302,589 Tbet expression by immune cells and in particular T-cells. Based on this discovery, and in view of the known immu (22) PCT Fed: Apr. 9, 2015 nosuppressive effect of PD-1 on immunity and the promot ing effect of Tbet on T cell immunity, the present invention (86) PCT No.: PCT/B2O15/OS2606 relates to the use of GSK-3 inhibitors to promote immunity, S 371 (c)(1), including cytotoxic T cell immunity in Subjects in need (2) Date: Oct. 7, 2016 thereof, especially subjects with chronic conditions wherein inhibiting PD-1 expression and/or blockade or Tbet up Related U.S. Application Data regulation is therapeutically desirable Such as cancer and infectious conditions. Further, based on this discovery the (60) Provisional application No. 61/977.340, filed on Apr. present invention relates to the use of compounds which 9, 2014. promote GSK-3 expression or activity to Suppress immunity, especially aberrant T cell immunity in Subjects in need Publication Classification thereof, e.g., subjects with chronic conditions wherein PD-1 (51) Int. C. upregulation or Tbet down regulation is therapeutically A6 IK 3/404 (2006.01) desirable Such as allergic, autoimmune or inflammatory A6 IK3I/506 (2006.01) conditions. Also, screening methods for identifying immune A6 IK 38/10 (2006.01) agonists and antagonists, especially antibodies, are pro A6 IK 3/426 (2006.01) vided. Patent Application Publication Jun. 15, 2017 Sheet 3 of 20 US 2017/O165230 A1 "e CO CO G e V w G e CO shcy) w O H O CC D N O N e C 2 s. So S 3 2 s so g g g g g XBNJO 96 XBNJO % XeWJO % b cy) S. SC ', a a a Y O O N d r w e ad co ced to ced ed go ko r on d cd co do a d o o o o tes w d oo co r N d do so r n r Y XeWJO 96 XENO % Patent Application Publication US 2017/O165230 A1 ceWO % 00; 08 09 0;} 02 Xew Z?un6|- Patent Application Publication Jun. 15, 2017 Sheet 5 of 20 US 2017/O165230 A1 O C S. w w ? O O S S. west ws O yon - Of v- o cr) a t a ?h w"c ch S. d s wer O CC ce O d O wa wa x - S 3 3 S. Sow 3C 3 &d yd c& O 9 g to est didO r XeNJO 96 XeWJO % XeNJO % ve ve- w ad d wo ver - 3. 2 2 3 9Y a w in O - e n b wo- 9 wo d <C ? O 9 g o do or S S 3 S S o co So &C 3o S.O S.C d co Oe o co w \ wo- ... v. : CD CD XeWJO % CD xeWJO % XeWJO 9% - - Patent Application Publication Jun. 15, 2017 Sheet 6 of 20 US 2017/O165230 A1 gd ? S S. d op f N C N M OY m /2 CY) O CO - OO N 8 N OZOL 3. n CO66&IHO CC CY) 977 OW-AW ?h C SUU-909 E CC 98CC 78S 99.19C8S JOCUU ON c5 V CN - 6u)Sey 3SO w 5CD 59 w CD (WI) Al-Suelu - edueoSeOn. UeeW Patent Application Publication Jun. 15, 2017. Sheet 8 of 20 US 2017/O165230 A1 Patent Application Publication Jun. 15, 2017. Sheet 10 of 20 US 2017/0165230 A1 i (, a i. H 33 s 1s i O & 7o H. g. & S s a o H S 7o H S (/)on i O H 62. 7o H Sgo 9 “s, i. H Wss O H| a o ci H a H i o H -22 H 3 8 3 S S 3 c 3 3 S 3 S 3 S 3 8 cy cy N c - we C O c CN N ver wr O O (HOdVS). Od) (HOldWS).led.) uOSSeudxe eues enee uOSSeidxe eues eNee Patent Application Publication Jun. 15, 2017. Sheet 11 of 20 US 2017/O165230 A1 <—queuuqeeu,6nuqsnið Patent Application Publication Jun. 15, 2017. Sheet 12 of 20 US 2017/0165230 A1 < o veO rt S.s won O N. CO st SC Of O 5 N, OS d\9 st 5 g r s os GaS as 9 stGa S. O. w ass O Yi. So rt So 6s asD N N cy8 (N& CN3 to wae g o COQ 3to Sn 3co 8ci 8 o (HOld W9):Old) CD : uOSseudxe eues) enee (HOldW5):leqL) uOSSeidke eues) emele 4. 5 992 o oco N.O &d O eZSJOu enlee Patent Application Publication Jun. 15, 2017. Sheet 13 of 20 US 2017/O165230 A1 Patent Application Publication |009|00't (HOldWo:Old) uoisseudxe eues) emee. Patent Application Publication US 2017/O165230 A1 Patent Application Publication Jun. 15, 2017. Sheet 17 of 20 US 2017/0165230 A1 5. E s 5. t * . E s < O t; o O V - 8 g g g g o - v- Xe NO % 5. CD e -o it (HOdWS):-Old) O s a ?al uoisseudx eues) enee uoissedX eues) enee e 8 o ox o c. c. a co to r w w" wo s vero O N wn wo wo d o O to oxid or on to CD 9vom edtoo oco ow oc o was co :www. Xe/NO % S.e XeWO % XENO % Patent Application Publication Jun. 15, 2017. Sheet 18 of 20 US 2017/0165230 A1 8 d Y v w w e es COH 2LL 'e 1, < D O s re d d d d d ed e co to r \ S 3 S. So X2NN JOOO % r XeNJO % " e . w s 2 v-?h 2, 1 e 2e O Y Y - (N N s s N C re S 3 as so S is as so 8 g : S. So XeWJO % XeWJO % XeWJO % CC CN O Patent Application Publication Jun. 15, 2017. Sheet 19 of 20 US 2017/0165230 A1 e w CN 2ar 2. COa a O?h or O al s s """ 33 & so 8 co to ri cn 0 % + N. XeNJO % s o CN V- O e- Of) Z - al L- o o o s CN Y. cN se s V- w AISueu XeWJO % 2 S 2. CD 5 O c\ e -2 Ni e co to x N Xe/NJO % Xe/NJO % ?h CN CN vm vm L US 2017/O165230 A1 Jun. 15, 2017 USE OF GSK-3 INHIBITORS OR tion factors, including activator protein-1; cyclic AMP ACTIVATORS WHICH MODULATE PD-1 OR response element binding protein (CREB); the nuclear factor T-BET EXPRESSION TO MODULATE T (NF) of activated T-cells; heat shock factor-1; B-catenin: CELL IMMUNITY c-Jun, c-Myc, c-Myb; and NF-KB See, for example, C. A. Grimes, et al., Prog. Neurobiol. 65, 391-426 (2001), H. RELATED APPLICATIONS Eldar-Finkelman, Trends in Molecular Medicine, 8, 126-132 0001. The present application claims benefit of priority to (2002), and P. Cohen, et al., Nature, 2, 1-8, (2001). Accord U.S. provisional application No. 61/977.340 filed on Apr. 9. ingly, targeting the activity of GSK-3 has significant thera 2014, the contents of which are incorporated by reference peutic potential in the treatment of many disparate patholo herein. gies and conditions, for example, Alzheimer's disease (A. Castro, et al., Exp. Opin. Ther. Pat., 10, 1519-1527 (2000)); FIELD asthma (P. J. Barnes, Ann. Rev. Pharmacol. Toxicol., 42, 81-98 (2002)); cancer (Beals, et al., Science, 275, 1930 0002 The present application generally relates to the 1933 (1997), L. Kim, et al., Curr. Opin. Genet. Dev., 10, discovery that glycogen synthase kinase 3 (GSK-3) is an 508-514 (2000), and Q. Eastman, et al., Curr. Opin. Cell upstream signalling molecule that controls PD-1 transcrip Biol., 11, 233 (1999); diabetes and its related sequelae, for tion and Tbet expression by immune cells and in particular example, Syndrome X and obesity (S. E. Nikoulina, et al., expression thereof by T-cells. Based on this discovery, and Diabetes, 51, 2190-2198 (2002), Orena, et al., JBC, 15765 in view of the known immunosuppressive effect of PD-1 on 15772 (2000), and Summers, et al., J. Biol. Chem., 274 immunity and the promoting effect of Tbet on T cell immu 17934-17940 (1999)); hair loss (S. E. Millar, et al., Dev. nity, the present invention relates to the use of GSK-3 Biol. 207, 133-149 (1999) and E. Fuchs, et al., Dev. Cell, 1, inhibitors to promote immunity, including cytotoxic T cell 13-25 (2001)); inflammation (P.
Load more

Recommended publications
  • Cyprinus Carpio
    Académie Universitaire Wallonie - Europe Université de Liège Faculté de Médecine Vétérinaire Département des Maladies Infectieuses et Parasitaires Service d’Immunologie et de Vaccinologie Etude des portes d’entrée de l’Herpèsvirus cyprin 3 chez Cyprinus carpio Study of the portals of entry of Cyprinid herpesvirus 3 in Cyprinus carpio Guillaume FOURNIER Thèse présentée en vue de l’obtention du grade de Docteur en Sciences Vétérinaires Année académique 2011-2012 Académie Universitaire Wallonie - Europe Université de Liège Faculté de Médecine Vétérinaire Département des Maladies Infectieuses et Parasitaires Service d’Immunologie et de Vaccinologie Etude des portes d’entrée de l’Herpèsvirus cyprin 3 chez Cyprinus carpio Study of the portals of entry of Cyprinid herpesvirus 3 in Cyprinus carpio Promoteur : Prof. Alain Vanderplasschen Guillaume FOURNIER Thèse présentée en vue de l’obtention du grade de Docteur en Sciences Vétérinaires Année académique 2011-2012 « La science progresse en indiquant l'immensité de l'ignoré. » Louis Pauwels Remerciements Liège, le 15 février 2012 L’accomplissement d’une thèse est un long et palpitant voyage en océan où se mélangent la curiosité, le doute, la persévérance, et la confiance… en soi bien sûr, mais surtout envers toutes les personnes qui, par leurs conseils, leur aide, leur soutien m’ont permis de mener cette thèse à bien. Je tiens ici à remercier mes collègues, amis et famille qui ont été tantôt les phares, tantôt les boussoles, toujours les fidèles compagnons de cette aventure. Je commencerais par adresser mes plus sincères remerciements à mon promoteur, le Professeur Alain Vanderplasschen, qui m’avait déjà remarqué en amphithéâtre pour ma curiosité, à moins que ce ne soit pour mon irrésistible coiffure..
    [Show full text]
  • Expression of the P53 Inhibitors MDM2 and MDM4 As Outcome
    ANTICANCER RESEARCH 36 : 5205-5214 (2016) doi:10.21873/anticanres.11091 Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer MAXIMILIAN CHRISTIAN KRIEGMAIR 1* , MA TT HIAS BALK 1, RALPH WIRTZ 2* , ANNETTE STEIDLER 1, CLEO-ARON WEIS 3, JOHANNES BREYER 4* , ARNDT HARTMANN 5* , CHRISTIAN BOLENZ 6* and PHILIPP ERBEN 1* 1Department of Urology, University Medical Centre Mannheim, Mannheim, Germany; 2Stratifyer Molecular Pathology, Köln, Germany; 3Institute of Pathology, University Medical Centre Mannheim, Mannheim, Germany; 4Department of Urology, University of Regensburg, Regensburg, Germany; 5Institute of Pathology, University Erlangen-Nuernberg, Erlangen, Germany; 6Department of Urology, University of Ulm, Ulm, Germany Abstract. Aim: To evaluate the prognostic role of the p53- Urothelical cell carcinoma (UCC) of the bladder is the second upstream inhibitors MDM2, MDM4 and its splice variant most common urogenital neoplasm worldwide (1). Whereas MDM4-S in patients undergoing radical cystectomy (RC) for non-muscle invasive UCC can be well treated and controlled muscle-invasive bladder cancer (MIBC). Materials and by endoscopic resection, for MIBC, which represents 30% of Methods: mRNA Expression levels of MDM2, MDM4 and tumor incidence, radical cystectomy (RC) remains the only MDM4-S were assessed by quantitative real-time polymerase curative option. However, MIBC progresses frequently to a chain reaction (qRT-PCR) in 75 RC samples. Logistic life-threatening metastatic disease with limited therapeutic regression analyses identified predictors of recurrence-free options (2). Standard clinical prognosis parameters in bladder (RFS) and cancer-specific survival (CSS). Results: High cancer such as stage, grade or patient’s age, have limitations expression was found in 42% (MDM2), 27% (MDMD4) and in assessing individual patient’s prognosis and response to 91% (MDM4-S) of tumor specimens.
    [Show full text]
  • Molecular Identification and Genetic Characterization of Cetacean Herpesviruses and Porpoise Morbillivirus
    MOLECULAR IDENTIFICATION AND GENETIC CHARACTERIZATION OF CETACEAN HERPESVIRUSES AND PORPOISE MORBILLIVIRUS By KARA ANN SMOLAREK BENSON A THESIS PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE UNIVERSITY OF FLORIDA 2005 Copyright 2005 by Kara Ann Smolarek Benson I dedicate this to my best friend and husband, Brock, who has always believed in me. ACKNOWLEDGMENTS First and foremost I thank my mentor, Dr. Carlos Romero, who once told me that love is fleeting but herpes is forever. He welcomed me into his lab with very little experience and I have learned so much from him over the past few years. Without his excellent guidance, this project would not have been possible. I thank my parents, Dave and Judy Smolarek, for their continual love and support. They taught me the importance of hard work and a great education, and always believed that I would be successful in life. I would like to thank Dr. Tom Barrett for the wonderful opportunity to study porpoise morbillivirus in his laboratory at the Institute for Animal Health in England, and Dr. Romero for making the trip possible. I especially thank Dr. Ashley Banyard for helping me accomplish all the objectives of the project, and all the wonderful people at the IAH for making a Yankee feel right at home in the UK. I thank Alexa Bracht and Rebecca Woodruff who have been with me in Dr. Romero’s lab since the beginning. Their continuous friendship and encouragement have kept me sane even in the most hectic of times.
    [Show full text]
  • Medsafe Sheet for Copaxone
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME COPAXONE® 20 mg/mL PRE-FILLED SYRINGE COPAXONE® 40 mg/mL PRE-FILLED SYRINGE 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Copaxone 20 mg/mL contains 20 mg of glatiramer acetate. Copaxone 40 mg/mL contains 40 mg of glatiramer acetate. Glatiramer acetate, the active ingredient in both Copaxone 20 mg/mL and Copaxone 40 mg/mL, is the acetate salt of synthetic polypeptides, containing four naturally occurring amino acids: L-glutamic acid, L-alanine, L-tyrosine and L-lysine with an average molar fraction 0.141, 0.427, 0.095 and 0.338, respectively. The average molecular weight of glatiramer acetate is 5000 to 9000 Daltons. For a full list of excipients, see section 6.1 List of excipients. 3. PHARMACEUTICAL FORM Copaxone is a clear, colourless solution for injection, in a pre-filled syringe. The pH of a 0.5% solution in water is in the range of 5.5 to 7.0 and an osmolarity of about 265 mOsmol/L and 300 mOsmol/L for the 20 mg/mL and 40 mg/mL, respectively. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Reduction of the frequency of relapses in patients with Relapsing Remitting Multiple Sclerosis. Treatment of patients with a single clinical event suggestive of multiple sclerosis and at least two clinically silent MRI lesions characteristic of multiple sclerosis, if alternative diagnoses have been excluded. 4.2 Dose and method of administration The only recommended route of administration of Copaxone injection is by the subcutaneous route. Copaxone should not be administered by the intravenous or intramuscular routes.
    [Show full text]
  • United States Patent (10) Patent No.: US 9,724,354 B2 Brake Et Al
    USOO9724354B2 (12) United States Patent (10) Patent No.: US 9,724,354 B2 Brake et al. (45) Date of Patent: Aug. 8, 2017 (54) COMBINATION OF CATALYTIC MTORC1/2 6,727.251 B2 4/2004 Bebbington et al. INHIBITORS AND SELECTIVE INHIBITORS g: R 1939: Shano et al. O OF AURORAAKNASE 7,049,116 B2 5, 2006 Shokat 7,148,228 B2 12/2006 Kasibhatla et al. (71) Applicant: Millennium Pharmaceuticals, Inc., 7,271,262 B2 9, 2007 tty al Cambridge, MA (US) 7,572,784 B2 8/2009 Claiborne et al. 8,026,246 B2 9, 2011 Claiborne et al. (72) Inventors: Rachael L. Brake, Natick, MA (US); 8,399.659 B2 3/2013 Claiborne et al. Huifeng Niu, Cambridge, MA (US) 9,102,678 B2 8, 2015 Claiborne et al. g Nu, 2C, 2001/0024.833 A1 9, 2001 Laborde et al. 2002fOO16976 A1 2/2002 Shokat (73) Assignee: Millennium Pharmaceuticals, Inc., 2002fO156081 A1 10, 2002 Hirst et al. Cambridge, MA (US) 2003/0022885 A1 1/2003 Bebbington et al. 2003/0055068 A1 3/2003 Bebbington et al. c - r 2003. O180924 A1 9, 2003 DeSimone (*) Notice: Sibi tO E. site th still 2003/0187001 A1 10, 2003 Calderwood et al. patent 1s extended or adjusted under 2005/0085472 A1 4/2005 Tanaka et al. U.S.C. 154(b) by 0 days. 2005. O197340 A1 9, 2005 Arora et al. 2006,0074074 A1 4/2006 Ohtsuka et al. (21) Appl. No.: 14/777,888 2006/0235031 A1 10, 2006 Arnold et al. 2006/0246551 A1 11/2006 Stack et al.
    [Show full text]
  • Human Anatomy As Related to Tumor Formation Book Four
    SEER Program Self Instructional Manual for Cancer Registrars Human Anatomy as Related to Tumor Formation Book Four Second Edition U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutesof Health SEER PROGRAM SELF-INSTRUCTIONAL MANUAL FOR CANCER REGISTRARS Book 4 - Human Anatomy as Related to Tumor Formation Second Edition Prepared by: SEER Program Cancer Statistics Branch National Cancer Institute Editor in Chief: Evelyn M. Shambaugh, M.A., CTR Cancer Statistics Branch National Cancer Institute Assisted by Self-Instructional Manual Committee: Dr. Robert F. Ryan, Emeritus Professor of Surgery Tulane University School of Medicine New Orleans, Louisiana Mildred A. Weiss Los Angeles, California Mary A. Kruse Bethesda, Maryland Jean Cicero, ART, CTR Health Data Systems Professional Services Riverdale, Maryland Pat Kenny Medical Illustrator for Division of Research Services National Institutes of Health CONTENTS BOOK 4: HUMAN ANATOMY AS RELATED TO TUMOR FORMATION Page Section A--Objectives and Content of Book 4 ............................... 1 Section B--Terms Used to Indicate Body Location and Position .................. 5 Section C--The Integumentary System ..................................... 19 Section D--The Lymphatic System ....................................... 51 Section E--The Cardiovascular System ..................................... 97 Section F--The Respiratory System ....................................... 129 Section G--The Digestive System ......................................... 163 Section
    [Show full text]
  • Information for Authors / Submission Process New
    INFORMATION FOR AUTHORS / SUBMISSION PROCESS NEW Electronic Submission Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for As of December 1, 2007, the Canadian Journal of Neurological Biomedical Publication International Committee of Sciences went to an Electronic Submission process. ALL manuscript submissions will be handled by an On-Line tracking system. Go to Medical Journal Editors www.cjns.org and click on SUBMIT YOUR MANUSCRIPT and For detailed instructions regarding style and layout refer to "Uniform follow the instructions. requirements for manuscripts submitted to biomedical journals". Copies of this document may be obtained on the website (we will no longer accept paper/disc submissions) http://www.icmje.org. Articles should be submitted under The manuscript submission process is broken into a series of five conventional headings of introduction, methods and materials, screens that gather detailed information about your manuscript and results, discussion, but other headings will be considered if more allow you to upload the pertinent files. The sequence of screens are as suitable. For Uniform Requirements for Sample References go to follows: http://www.nlm.nih.gov/bsd/uniform_requirements.html. After the manuscript is submitted, you will be asked to select the order you would like the files to be displayed in a merged PDF file 1. A long form asking for author information, title, abstract, and file that the system will create for you. Next, you will be directed to a quantities. page that will allow you to review your converted manuscript. If the 2. A screen asking for the actual file locations on your computer (via conversion is not correct, you can replace or delete your manuscript an open file dialog).
    [Show full text]
  • Antagonists of Il-6 to Prevent Or Treat
    (19) TZZ ¥_ _T (11) EP 2 376 126 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 39/00 (2006.01) C07K 16/24 (2006.01) 20.12.2017 Bulletin 2017/51 (86) International application number: (21) Application number: 09830695.4 PCT/US2009/006266 (22) Date of filing: 24.11.2009 (87) International publication number: WO 2010/065077 (10.06.2010 Gazette 2010/23) (54) ANTAGONISTS OF IL-6 TO PREVENT OR TREAT THROMBOSIS ANTAGONISTEN VON IL-6 ZUR PRÄVENTION ODER BEHANDLUNG VON THROMBOSE ANTAGONISTES D IL-6 POUR PRÉVENIR OU TRAITER LA THROMBOSE (84) Designated Contracting States: • MATSUYAMA MASASHI ET AL: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR "Anti-interleukin-6 receptor antibody HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL (tocilizumab) treatment of multicentric PT RO SE SI SK SM TR Castleman’s disease", INTERNAL MEDICINE, JAPANESE SOCIETY OF INTERNAL MEDICINE, (30) Priority: 05.02.2009 US 366567 TOKYO, JP; BIOSCIENCES INFORMATION 14.07.2009 US 502581 SERVICE, PHILADELPHIA, PA, US, vol. 46, 1 25.11.2008 US 117811 P January 2007 (2007-01-01), pages 771-774, 25.11.2008 US 117861 P XP002696891, ISSN: 0918-2918, DOI: 24.02.2009 US 391717 10.2169/INTERNALMEDICINE.46.6262 06.03.2009 US 399156 • EMILLE D ET AL: "ADMINISTRATION OF AN 25.11.2008 US 117839 P ANTI-INTERLEUKIN-6 MONOCLONAL 24.02.2009 US 391615 ANTIBODY TO PATIENTS WITH ACQUIRED IMUNODEFICIENCY SYNDROME AND (43) Date of publication of application: LYMPHOMA: EFFECT ON LYMPHOMA GROWTH 19.10.2011 Bulletin 2011/42 AND ON B CLINICAL SYMPTOMS", BLOOD, AMERICAN SOCIETY OFHEMATOLOGY, US, vol.
    [Show full text]
  • Incidence of Urogenital Neoplasms in India
    Published online: 2021-06-17 Original Article Incidence of Urogenital Neoplasms in India Abstract Satyanarayana Objective: To study and compare the national and regional incidences and risk of developing Labani, of neoplasms of individual urogenital sites using 2012 – 2014 reports from the National Cancer Dishank Rawat, Registry Programme (NCRP) data. Materials and Methods: A number of incident cases, age- adjusted rates (AARs), and cumulative risk (0 – 64 years) pertaining to urogenital neoplasms, along Smita Asthana with the ICD-10 codes, were extracted. Data on indicators, namely number of incident cases, AARs Division of Epidemiology and one in a number of persons develop cancer were summarized for both the sexes in each of the and Biostatistics, Institute of Cytology and Preventive cancer registries and presented region-wise in the form of ranges. The proportion of all Results: Oncology, Indian Council of urogenital neoplasms in comparison to all cancers was 12.51% in women and 5.93% in men. Risk of Medical Research, Noida, development of urogenital cancers for women was maximum (1 in 50) in the North-eastern region, Uttar Pradesh, India followed by Rural West, South, and North. For men, the risk of developing neoplasms of urogenital sites was highest (1 in 250). For the neoplasms of the renal pelvis and ureter, both the incidence and risk were quite low for all genders across all the regions. Cervical neoplasms had the highest incidence (4.91 – 23.07) among female genital neoplasms, while prostate had the highest incidence (0.82 – 12.39) among male genital neoplasms. Conclusion: Making people aware of urogenital neoplasms and their risk factors are important for the public health awareness point of view.
    [Show full text]
  • Male Urogenital Cancers in Suriname 199
    Academic Journal of Suriname 2011, 2, 198-204 Biomedicine Full-length paper The incidence of malignancies of the male urogenital system in the Republic of Suriname from 1980 through 2004 Dennis R.A. Mans 1, Santosh S. Sardjoe 1, Martinus A. Vrede 2 1Department of Pharmacology, Faculty of Medical Sciences, Anton de Kom University of Suriname, Paramaribo, Suriname; 2Department of Pathology, Faculty of Medical Sciences, Anton de Kom University of Suriname, Paramaribo, Suriname Abstract The worldwide occurrence of male urogenital malignancies (cancers of prostate, penis, and testes, as well as those of kidneys and urinary bladder of men) varies from exceedingly rare to very common. In this study, incidence rates of these neoplasms in the Republic of Suriname between 1980 and 2004 have been assessed and compared with international data. Patient information was obtained from the Pathologic Anatomy Laboratory, population data from the General Bureau of Statistics. Sex-specific rates were calculated for cancer overall and for all anatomical sites, and stratified according to age groups 0 to 19, 20 to 49, and 50+ years, as well as the largest ethnic groups, viz. Hindustani, Creole, and Javanese. From these data, average yearly numbers and average rates per 100,000 men per year were calculated and expressed as means ± SDs. There were nearly 900 male urogenital malignancies in the period covered by this study, which corresponded to an overall rate of approximately 17. The most common urogenital neoplasm by far was prostatic cancer, occurring in more than three- quarters of cases and at a rate of about 13. Kidney, urinary bladder, penile, and testicular cancer were seen at rates lower than 2.
    [Show full text]
  • Risk Assessment Report Arsenic in Foods (Chemicals and Contaminants)
    [Tentative translation] Risk Assessment Report Arsenic in foods (Chemicals and Contaminants) Food Safety Commission Japan (FSCJ) October 2013 0 [Tentative translation] Contents Page Chronology of Discussions .................................................................................................... 3 List of members of the Food Safety Commission .................................................................. 3 List of members of the EPCC, the Food Safety Commission ................................................ 4 Executive summary ................................................................................................................ 6 I. Background ......................................................................................................................... 9 II. Outline of the Substances under Assessment .................................................................... 9 1. Physiochemical properties ......................................................................................... 9 (1) Metallic arsenic ................................................................................................... 9 (2) Inorganic arsenic compounds ........................................................................... 10 (3) Organic arsenic compounds .............................................................................. 12 (4) Analytical methods for arsenic ......................................................................... 16 2. Major use and production .......................................................................................
    [Show full text]
  • This Thesis Has Been Submitted in Fulfilment of the Requirements for a Postgraduate Degree (E.G
    This thesis has been submitted in fulfilment of the requirements for a postgraduate degree (e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following terms and conditions of use: • This work is protected by copyright and other intellectual property rights, which are retained by the thesis author, unless otherwise stated. • A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. • This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author. • The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author. • When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given. Marek’s Disease Virus Pathogenesis and Latency Gillian Hunter M Phil The University of Edinburgh 2012 i DECLARATION I declare that all work included in this thesis has been composed by myself. Contributions to the work of this thesis by colleagues are fully acknowledged. No part of this work has been or will be submitted for any other degree or qualification. Gillian Hunter January 28, 2011 Centre for Infectious Diseases The Roslin Institute Royal (Dick) School of Veterinary Studies Summerhall Tower Block University of Edinburgh Edinburgh EH9 1QH ii ABSTRACT Marek’s Disease virus (MDV) is a highly contagious, widespread and persistent neoplastic herpesvirus causing extensive lymphoblastic tumours in chickens. The virus is shed in feather dust and spread through inhalation. Vaccines are available to protect against the effects of MDV but not replication of the virus and subsequent contamination of the environment leading to flock exposure.
    [Show full text]